olivLaw · US equity research
Cryo-Cell International, Inc. CCEL
Services-Misc Health & Allied Services, NEC · SIC 8090 · Vertical: Services-Misc Health & Allied Services, NEC (SIC 8090)
Cryo-Cell International is one of the oldest private cord blood banks in the world, storing specimens for families and offering biostorage services. Revenue edged down in fiscal 2025 and the company has paused projects tied to its Duke license, which raises questions about its future direction.
At the close of 04 Nov 2026, Cryo-Cell International, Inc. (CCEL) stock was 5.07 USD (+0.40% on the day), with market capitalisation 40.9 m USD, dividend yield 4.93%, beta 0.25, 52-week range 2.89–5.35 USD. Latest reported quarter (Q3 2026): revenue of 7.8 m USD (−0.0% YoY), net income of 1.3 m USD (+69.5% YoY), diluted EPS 0.16 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 59.1
- strong (55–70)
- Bollinger (20, 2)
- 3.82 – 5.54
- in the upper half of the band · %B 0.73 · band width 36.8%
- SMA 50 / 200
- 4.35 / 3.70
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.27 / 0.23
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +36.7% | −1.1% | +37.8 pp | — |
| 3 months | +39.3% | −0.5% | +39.7 pp | — |
| 6 months | +43.6% | +4.4% | +39.2 pp | — |
| Year to date | +47.4% | +12.3% | +35.1 pp | — |
| 1 year | +16.8% | +13.5% | +3.3 pp | +14.1% |
| 3 years | 0.0% | +76.4% | −76.4 pp | −12.4% |
| 5 years | −58.6% | +63.7% | −122.3 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 31 Aug 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.0 m | 8.0 m | 7.9 m | 7.8 m | 7.8 m | 7.7 m | 7.8 m | 7.8 m |
| Cost of revenue | 1.6 m | 2.0 m | 1.9 m | 1.8 m | 1.7 m | 1.7 m | 1.7 m | 1.6 m |
| Research & development | 304.6 k | 98.1 k | 131.7 k | 61.6 k | 84.8 k | 65.8 k | 99.8 k | 53.6 k |
| SG&A | 6.0 m | 4.6 m | 4.3 m | 3.9 m | 5.4 m | 5.0 m | 4.6 m | 3.8 m |
| Operating income | -122.3 k | 1.1 m | 1.5 m | 1.9 m | -4.0 m | 765.1 k | 1.2 m | 2.2 m |
| Depreciation & amortisation | 249.0 k | 248.0 k | 190.1 k | 185.7 k | 243.0 k | 244.2 k | 184.3 k | 184.5 k |
| Interest expense | 745.5 k | 495.0 k | 551.1 k | 538.2 k | 481.9 k | 462.7 k | 441.9 k | 438.3 k |
| Pre-tax income | -842.4 k | 533.7 k | 575.1 k | 1.2 m | -4.6 m | 70.3 k | 827.8 k | 1.8 m |
| Income tax | 1.0 m | 250.9 k | 219.3 k | 436.6 k | -814.5 k | 23.2 k | 273.2 k | 555.0 k |
| Net income | -1.9 m | 282.9 k | 355.8 k | 749.4 k | -3.8 m | 47.1 k | 554.6 k | 1.3 m |
| Diluted EPS | -0.23 ≈ | 0.03 | 0.04 | 0.09 | -0.48 ≈ | 0.01 | 0.07 | 0.16 |
| Operating cash flow | 2.2 m | 954.1 k | 707.0 k ≈ | 2.5 m ≈ | 1.3 m | 651.8 k | 1.8 m ≈ | 1.1 m ≈ |
| Capex | 8.3 k | 62.1 k | 62.4 k ≈ | 38.8 k ≈ | 67.2 k | 67.1 k | 32.7 k ≈ | 101.9 k ≈ |
| Dividends paid | 2.0 m | 2.0 m | 1.2 m ≈ | 0 ≈ | 0 | 0 | 0 ≈ | 0 ≈ |
| Share repurchases | 0 | 0 | 88.6 k ≈ | 80.9 k ≈ | 0 | — | — | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29.2 m | 31.8 m | 31.1 m | 28.9 m | 30.3 m | 31.3 m | 32.0 m | 31.6 m |
| Revenue YoY | +15.1% | +8.9% | −2.1% | −7.3% | +5.0% | +3.3% | +2.0% | −1.3% |
| Net income | -854.8 k | 2.3 m | 3.6 m | 2.1 m | 2.8 m | -9.5 m | 402.1 k | -2.4 m |
| Net income YoY | −136.9% | unavailable | +58.2% | −42.5% | +33.0% | −443.6% | unavailable | −704.2% |
| Diluted EPS | -0.11 | 0.27 | 0.45 | 0.25 | 0.33 | -1.14 | 0.05 | -0.30 |
| Diluted EPS YoY | −136.7% | unavailable | +66.7% | −44.4% | +32.0% | −445.5% | unavailable | −700.0% |
| net % | -2.9% | 7.2% | 11.6% | 7.2% | 9.1% | -30.4% | 1.3% | -7.7% |
| Free cash flow | 4.9 m | 5.6 m | 8.4 m | 6.1 m | -3.6 m | 2.1 m | 3.6 m | 5.2 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 30 Nov 2025
- Cash
- 319.0 k USD
- Financial debt
- 8.4 m USD
- Net debt
- 8.0 m USD
- Equity
- -18.6 m USD
- Total assets
- 61.7 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.59x
- ROE
- unavailable
- ROA
- -3.8%
- FCF margin
- 16.6%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 31.1 m | 28.9 m | 30.3 m | 31.3 m | 32.0 m | 31.6 m | SEC (XBRL)· 27 Feb 2026verified |
| Cost of revenue | 9.7 m | 9.0 m | 8.8 m | 8.4 m | 7.9 m | 7.4 m | SEC (XBRL)· 27 Feb 2026verified |
| Gross profit | 21.5 m ≈ | 19.9 m ≈ | 21.5 m ≈ | 23.0 m ≈ | 24.0 m ≈ | 24.2 m ≈ | SEC (XBRL)· 27 Feb 2026derived |
| Research & development | 23.9 k | 49.9 k | 384.8 k | 1.2 m | 1.2 m | 376.3 k | SEC (XBRL)· 27 Feb 2026verified |
| SG&A | 14.3 m | 14.6 m | 15.6 m | 17.2 m | 18.5 m | 18.2 m | SEC (XBRL)· 27 Feb 2026verified |
| Operating income | 7.7 m | 4.0 m | 4.0 m | -12.3 m | 3.5 m | 482.4 k | SEC (XBRL)· 27 Feb 2026verified |
| Depreciation & amortisation | 372.3 k | 1.0 m | 1.5 m | 1.4 m | 693.8 k | 985.2 k | SEC (XBRL)· 27 Feb 2026verified |
| EBITDA | 8.0 m ≈ | 5.1 m ≈ | 5.5 m ≈ | -10.9 m ≈ | 4.2 m ≈ | 1.5 m ≈ | SEC (XBRL)· 27 Feb 2026derived |
| Interest expense | 1.5 m | 1.4 m | 1.5 m | 1.2 m | 1.9 m | 2.1 m | SEC (XBRL)· 27 Feb 2026verified |
| Pre-tax income | 5.0 m | 2.6 m | 3.3 m | -13.4 m | 2.8 m | -2.3 m | SEC (XBRL)· 27 Feb 2026verified |
| Income tax | 1.4 m | 527.7 k | 547.5 k | -3.8 m | 2.4 m | 92.2 k | SEC (XBRL)· 27 Feb 2026verified |
| Net income | 3.6 m | 2.1 m | 2.8 m | -9.5 m | 402.1 k | -2.4 m | SEC (XBRL)· 27 Feb 2026verified |
| Diluted EPS | 0.45 | 0.25 | 0.33 | -1.14 | 0.05 | -0.30 | SEC (XBRL)· 27 Feb 2026verified |
| Weighted average diluted shares | 8.1 m | 8.4 m | 8.5 m | 8.3 m | 8.2 m | 8.1 m | SEC (XBRL)· 27 Feb 2026verified |
| Dividend per share | — | — | 0.90 | — | 0.25 | — | SEC (XBRL)· 28 Feb 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 10.4 m | 8.3 m | 1.7 m | 406.1 k | 561.0 k | 319.0 k | SEC (XBRL)· 27 Feb 2026verified |
| Receivables | 6.3 m | 5.3 m | 6.0 m | 6.6 m | 7.3 m | 6.8 m | SEC (XBRL)· 27 Feb 2026verified |
| Inventories | 927.3 k | 921.2 k | 851.2 k | 768.9 k | 657.7 k | 408.8 k | SEC (XBRL)· 27 Feb 2026verified |
| Current assets | 18.6 m | 15.8 m | 9.6 m | 9.5 m | 12.6 m | 11.8 m | SEC (XBRL)· 27 Feb 2026verified |
| Property, plant & equipment, net | 1.6 m | 3.2 m | 13.6 m | 21.0 m | 21.9 m | 21.0 m | SEC (XBRL)· 27 Feb 2026verified |
| Goodwill | 1.9 m | 1.9 m | 1.9 m | 1.9 m | 1.9 m | 1.9 m | SEC (XBRL)· 27 Feb 2026verified |
| Intangibles (excl. goodwill) | 1.2 m | 1.6 m | 1.5 m | 989.1 k | 921.3 k | 863.1 k | SEC (XBRL)· 27 Feb 2026verified |
| Total assets | 46.2 m | 60.7 m | 64.9 m | 64.7 m | 64.7 m | 61.7 m | SEC (XBRL)· 27 Feb 2026verified |
| Accounts payable | 957.4 k | 1.5 m | 1.6 m | 3.2 m | 1.9 m | 2.9 m | SEC (XBRL)· 27 Feb 2026verified |
| Long-term debt | 5.9 m | 1.9 m | 8.7 m | 8.6 m | 8.5 m | 8.4 m | SEC (XBRL)· 27 Feb 2026verified |
| Current liabilities | 16.4 m | 21.1 m | 19.5 m | 20.9 m | 21.6 m | 19.8 m | SEC (XBRL)· 27 Feb 2026verified |
| Total liabilities | 48.9 m | 56.5 m | 66.4 m | 72.3 m | 77.9 m | 80.3 m | SEC (XBRL)· 27 Feb 2026verified |
| Equity | -2.7 m † | 4.2 m † | -1.5 m † | -11.0 m † | -13.2 m † | -18.6 m † | SEC (XBRL)· 27 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 8.5 m | 7.9 m | 8.6 m | 8.9 m | 6.0 m | 5.5 m | SEC (XBRL)· 27 Feb 2026verified |
| Capex | 100.0 k | 1.8 m | 12.2 m | 6.8 m | 2.4 m | 230.5 k | SEC (XBRL)· 27 Feb 2026verified |
| Free cash flow | 8.4 m ≈ | 6.1 m ≈ | -3.6 m ≈ | 2.1 m ≈ | 3.6 m ≈ | 5.2 m ≈ | SEC (XBRL)· 27 Feb 2026derived |
| Investing cash flow | 357.5 k | -7.0 m | -15.3 m | -8.1 m | -4.9 m | -975.3 k | SEC (XBRL)· 27 Feb 2026verified |
| Financing cash flow | -5.0 m | -3.1 m | 147.9 k | -2.1 m | -979.1 k | -4.7 m | SEC (XBRL)· 27 Feb 2026verified |
| Dividends paid | — | 0 | 7.7 m | 0 | 2.0 m | 3.2 m | SEC (XBRL)· 27 Feb 2026verified |
| Share repurchases | — | 249.4 k | 1.8 m | 799.0 k | 1.4 m | 169.5 k | SEC (XBRL)· 27 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 23 / 100
A scoring methodology on indicators and valuation, not investment advice.
score < 40
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 40.9 m USD
Key indicators
Coverage and freshness
Score by group
- Balance sheet1
- Growth11
- Quality20
- Returns40
- Valuation44
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 3.29 – 15.55 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)9.41 – 15.55 (Mid 11.73)WACC 8.6% · starting FCFF 6.2 m USD · terminal value share of EV 75%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): -27.6%
- Peers: EV/EBITDAunavailable · insufficient data
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)3.29 – 4.42 (Mid 3.77)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Unattractive profile · Score 23/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -6.2% | 20 (vs peers) | 10% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 1.3% | 11 (on a fixed band) | 13% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | 6.5x | 0 (on a fixed band) | 16% |
| Interest coverage · Balance sheet | 0.1x | 0 (on a fixed band) | 10% |
| Current ratio · Balance sheet | 0.9x | 5 (on a fixed band) | 6% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | 45.6x | 0 (on a fixed band) | 16% |
| FCF yield · Valuation | 11.4% | 100 (on a fixed band) | 13% |
| Shareholder yield (distributions) · Returns | 0.0% | 0 (on a fixed band) | 10% |
| Payout ratio (FCF) · Returns | 0.0% | 100 (on a fixed band) | 6% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet1/100 · 3/3 factors with a value
- Growth· partial11/100 · 1/2 factors with a value
- Quality· partial20/100 · 1/3 factors with a value
- Returns40/100 · 2/2 factors with a value
- Valuation44/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
CRYO-CELL INTERNATIONAL, INC. (CCEL). Latest full fiscal year: 2025; data up to 2026-08-31.
Figures computed from the financial statements: revenue 31.6 m USD in 2025; YoY growth -1.3%; net margin -6.2%; net debt/EBITDA 6.5x.
The estimated value range is 6.35–9.98 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 7.75 USD, the price of 5.07 USD leaves a potential of 52.8% (value / price − 1) and a margin of safety of 34.6% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 23/100, methodological classification: unattractive profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: growth, quality. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF yield: 11.4%
- Payout ratio (FCF): 0.0%
- The price is below the estimated value range
What contradicts it
- Net margin: -6.2%
- Revenue CAGR 3Y: 1.3%
- Net debt / EBITDA: 6.5x
- Interest coverage: 0.1x
- Current ratio: 0.9x
- EV/EBITDA: 45.6x
- Shareholder yield (distributions): 0.0%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, P/E (TTM).
Versus the vertical median
Services-Misc Health & Allied Services, NEC (SIC 8090) · same industry (4-digit SIC) · compared with 10 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| DVADavita Inc. | 12.1 bn | 14.2 | — | 6.5% | +6.5% | +61% / +90% |
| FMSFresenius Medical Care AG | 6.5 bn | 6.9 | 7.0% | 5.0% | +1.5% | −3% / +13% |
| SHCSotera Health Company | 4.7 bn | 27.3 | 27.0% | 14.1% | +5.7% | −6% / +20% |
| PGNYProgyny, Inc. | 2.3 bn | 32.7 | 16.2% | 6.0% | +10.4% | +14% / −12% |
| AGLagilon health, inc. | 1.6 bn | 16.5 | -29.7% | -1.5% | −2.1% | +491% / −64% |
| VMDViemed Healthcare, Inc. | 383.1 m | 26.5 | 11.0% | 5.0% | +20.5% | +46% / +30% |
| CCELCryo-Cell International, Inc. | 40.9 m | — | — | -6.2% | −1.3% | +17% / 0% |
| BRTXBiorestorative Therapies, Inc. | 38.5 m | — | -241.1% | -3,089.6% | −10.3% | +40% / −21% |
| MGRXMangoceuticals, Inc. | 4.5 m | — | -95.1% | -4,791.3% | −26.0% | −81% / −98% |
| NIVFNewgenivf Group Limited | 166.5 k | 0.2 | 77.2% | 209.0% | −13.0% | −100% / −100% |
| MCTACharming Medical Limited | — | — | -0.9% | -0.5% | −22.7% | unavailable / unavailable |
1- and 3-year price returns: for CCEL from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Cryo-Cell International is one of the oldest private cord blood banks in the world, storing specimens for families and offering biostorage services. Revenue edged down in fiscal 2025 and the company has paused projects tied to its Duke license, which raises questions about its future direction.
SWOT
Strengths
Weaknesses
- The core segment depends almost entirely on one type of service, with small revenue from other lines 1.
- New enrollments have declined, and the company recorded a significant inventory impairment 1.
- Assets tied to the Duke license were fully written down, reflecting an investment that was not recovered 1.
Opportunities
Risks
- Dispute with Duke Universityhigh
The arbitration with Duke could affect expansion plans and costs, and the outcome is uncertain 1.
- Decline in new enrollmentshigh
If the number of new specimens keeps falling, revenue could be affected further 1.
- Inventory impairmentmedium
Recent write-downs of public inventory show that cost recovery can be uncertain 1.
- Capital needsmedium
The company could need additional funding if it resumes investment in the Duke license 1.
- Listing statusmedium
If the company fails to meet NYSE American continued listing standards, its shares could be delisted 1.
Investment thesis
What would need to be true (bull case)
What to watch
- Trend in new domestic specimens processedQ1 2027
- Progress of the ExtraVault project2027
- Decision on a regular quarterly dividend2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The company, incorporated in 1989 in Delaware, stores cord blood and cord tissue for family use, with over 250000 specimens 1. Operations are run from Oldsmar, Florida, and specimens are mainly stored at the Durham, North Carolina facility 1. It has also expanded into biostorage for third parties through ExtraVault 1.
Fiscal 2025 revenue of 31.6 million USD fell 1% from the prior year 1. After impairment indicators, the company fully wrote down the assets tied to the Duke license in fiscal 2023, and expansion into infusion and biopharmaceutical manufacturing now appears unlikely 1.
The company has also mentioned that its board was considering a regular quarterly dividend to shareholders, but this remains under consideration and has not been confirmed 3.
Segments
Market context
The market for cord blood stem cell storage remains niche, since most parents are unaware of the benefits and cord blood is often discarded as medical waste 1. Of the four million annual US births, only a small share participates in storage 1.
The company recently reported fewer new domestic specimens processed, which shows its core market may be shrinking 1. If this trend continues, revenue could remain under pressure.
Trends
- Decline in new enrollmentsheadwind
The number of new specimens processed fell in fiscal 2025, reducing processing revenue 1.
- Growth of recurring storage revenuetailwind
Revenue from annual storage fees increased, giving a steadier revenue base 1.
- Advances in regenerative medicinemixed
Progress in stem cell therapies could expand the usefulness of cord blood, but could also reduce the need for current services 1.
- Uncertainty over the Duke licenseheadwind
The dispute with Duke University has paused investment and clinic expansion, limiting near-term growth 1.
Competitive position
The company faces competition from public cord blood banks, especially in overseas markets but also in the United States 1. This competition could reduce the number of families choosing private storage 1.
The company differentiates its service through AABB and FACT accreditation, its PrepaCyte CB technology, and a payment warranty if a transplant fails to engraft 1.
- Public cord blood banks overseas
Competitors that could limit Cryo-Cell's share, especially in external markets 1.
- Public cord blood banks in the United States
Direct competition for the collection and distribution of cord blood units 1.
- Private cord blood banks in the United States
Competitors in family storage, where the company builds its client base 1.
- Biostorage providers for biopharmaceutical companies
Potential competitors for the ExtraVault service if it develops 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report28 Oct 2026Shareholder vote
- Proxy statement13 Oct 2026
- Quarterly report09 Oct 2026
- Current report14 Sept 2026Other events
- Quarterly report15 Jul 2026
- Current report08 May 2026Delisting notice · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report14 Apr 2026
- Current report12 Mar 2026Delisting notice · Regulation FD disclosure · Financial statements and exhibits
- Annual report27 Feb 2026
- Current report12 Nov 2025Other events
Sources
- [1] Form 10-K, fiscal year ended 2025-11-30 · SEC / Cryo-Cell International, Inc. · 27 Feb 2026
- [2] Form 10-Q, quarter ended 2026-08-31 · SEC / Cryo-Cell International, Inc. · 09 Oct 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Cryo-Cell International, Inc. · 17 Oct 2024
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.